AR064406A1 - Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente - Google Patents
Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondienteInfo
- Publication number
- AR064406A1 AR064406A1 ARP070105681A ARP070105681A AR064406A1 AR 064406 A1 AR064406 A1 AR 064406A1 AR P070105681 A ARP070105681 A AR P070105681A AR P070105681 A ARP070105681 A AR P070105681A AR 064406 A1 AR064406 A1 AR 064406A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- alkyl
- compound
- composite
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 208000010392 Bone Fractures Diseases 0.000 abstract 2
- 206010017076 Fracture Diseases 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000002118 epoxides Chemical class 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 230000035876 healing Effects 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 230000002194 synthesizing effect Effects 0.000 abstract 2
- 125000001544 thienyl group Chemical group 0.000 abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 abstract 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 abstract 1
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 208000000038 Hypoparathyroidism Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 150000001414 amino alcohols Chemical class 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000001126 calcilytic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 150000002009 diols Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 208000030915 hypercalcemia disease Diseases 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 230000004079 mineral homeostasis Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 201000008968 osteosarcoma Diseases 0.000 abstract 1
- 230000000849 parathyroid Effects 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 238000007070 tosylation reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Compuesto calcilítico derivado de (halo-fenilcarboxil)-hidroxietilamina de la formula (1): en la que: X es halogeno; Y es hidrogeno o halogeno; Z es -CO(O)H o -C(O)O-alquilo C1-5; R2 es alquilo C1-5; R3 es fenilo, tienilo, naftilo o dihidroindenilo, donde los restos tienilo y fenilo están opcionalmente sustituidos, independientemente, una o dos veces, con halogeno, alquilo C1-5, alcoxi C1-5 o alquiltio C1-5; y A es un enlace covalente o alquilo C1-5; o una sal farmacéuticamente aceptable del mismo. Composicion farmacéutica que lo comprende y su uso para preparar un medicamento util para antagonizar un receptor de calcio, para tratar una enfermedad o trastorno que comprende una homeostasis osea o mineral anormal como ser osteosarcoma, enfermedad periodontal, curacion de fracturas, osteoartritis, artritis reumatoide, enfermedad de Paget, hipoparatiroidismo, hipercalcemia humoral asociada con malignidad y curacion de fracturas, osteoporosis, osteoporosis o para aumentar los niveles paratiroideos séricos. Dicho uso donde el compuesto de la formula (1) se co-administra con un agente contra la resorcion. Método para sintetizar dicho compuesto y compuesto intermedio correspondiente. Reivindicacion 48: Un método para sintetizar un compuesto de acuerdo con la reivindicacion 1, caracterizado porque comprende las etapas de: (a) tosilacion selectiva de un diol de acuerdo con la formula (2), en la que R8 es alquilo C1-5, y X Y y R2 son como se han definido para la formula (1) en la reivindicacion 1; para producir un tosilato de acuerdo con la formula (3), (b) reaccion del tosilato en presencia de una base para proporcionar un epoxido de acuerdo con la formula (4), y (c) apertura del epoxido con una amina primaria para proporcionar un amino alcohol de acuerdo con la formula (5). Reivindicacion 50: Un intermedio para el método de las reivindicaciones 47 a 49, caracterizado porque se selecciona entre el grupo que consiste en la formula (2), (3) y (4), en las que R8 es alquilo C1-5 y X, Y y R2 son como se han definido en la formula (1) en la reivindicacion 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87043206P | 2006-12-18 | 2006-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064406A1 true AR064406A1 (es) | 2009-04-01 |
Family
ID=39536720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105681A AR064406A1 (es) | 2006-12-18 | 2007-12-18 | Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7902394B2 (es) |
| EP (1) | EP2120898A4 (es) |
| JP (1) | JP2010513564A (es) |
| AR (1) | AR064406A1 (es) |
| CL (1) | CL2007003688A1 (es) |
| TW (1) | TW200845956A (es) |
| UY (1) | UY30801A1 (es) |
| WO (1) | WO2008077009A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2292592T3 (pl) | 2008-06-05 | 2013-01-31 | Asahi Kasei Pharma Corp | Związki sulfonamidowe i ich zastosowanie |
| JP5696156B2 (ja) | 2009-11-02 | 2015-04-08 | ファイザー・インク | ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体 |
| WO2013152476A1 (en) * | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Process for the preparation of benzylbenzene sglt2 inhibitors |
| US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
| WO2015101916A1 (en) * | 2013-12-30 | 2015-07-09 | Mylan Laboratories Ltd. | Process for the preparation of empagliflozin |
| CN105085278A (zh) * | 2015-08-07 | 2015-11-25 | 常州大学 | 一种2-甲基-1-取代苯基-2-丙胺类化合物的制备方法 |
| CN106117045A (zh) * | 2016-06-22 | 2016-11-16 | 北京阳光诺和药物研究有限公司 | 一种苯基丁酸的纯化方法 |
| CN115710158A (zh) * | 2021-08-23 | 2023-02-24 | 凯特立斯（深圳）科技有限公司 | 一种不对称催化制备替格瑞洛中间体的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002522499A (ja) | 1998-08-12 | 2002-07-23 | スミスクライン・ビーチャム・コーポレイション | カルシウム分解化合物 |
| CO5180628A1 (es) | 1999-07-31 | 2002-07-30 | Smithkline Beecham Corp | Compuestos calcioliticos |
| MY143244A (en) | 2002-11-26 | 2011-04-15 | Smithkline Beecham Corp | Calcilytic compounds |
| DE102004021779A1 (de) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
-
2007
- 2007-12-17 TW TW096148160A patent/TW200845956A/zh unknown
- 2007-12-17 UY UY30801A patent/UY30801A1/es not_active Application Discontinuation
- 2007-12-18 AR ARP070105681A patent/AR064406A1/es unknown
- 2007-12-18 CL CL200703688A patent/CL2007003688A1/es unknown
- 2007-12-18 EP EP07855230A patent/EP2120898A4/en not_active Withdrawn
- 2007-12-18 US US12/518,482 patent/US7902394B2/en active Active
- 2007-12-18 WO PCT/US2007/087866 patent/WO2008077009A1/en not_active Ceased
- 2007-12-18 JP JP2009543128A patent/JP2010513564A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TW200845956A (en) | 2008-12-01 |
| CL2007003688A1 (es) | 2008-06-27 |
| EP2120898A4 (en) | 2011-08-03 |
| US20100029782A1 (en) | 2010-02-04 |
| EP2120898A1 (en) | 2009-11-25 |
| JP2010513564A (ja) | 2010-04-30 |
| US7902394B2 (en) | 2011-03-08 |
| UY30801A1 (es) | 2008-07-03 |
| WO2008077009A1 (en) | 2008-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064406A1 (es) | Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente | |
| UY30620A1 (es) | Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio | |
| CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
| BRPI0508622A (pt) | compostos de bifenil úteis como antagonistas do receptor muscarìnico | |
| DOP2010000103A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b | |
| BR112012019551A2 (pt) | moduladores seletivos do receptor de androgênio. | |
| BRPI0907844B8 (pt) | compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos | |
| UY27154A1 (es) | Pirimidinas inhibidoras de metaloproteinasa de matriz | |
| UY28482A1 (es) | Nuevos compuestos | |
| UY29004A1 (es) | Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso. | |
| BRPI0409680A (pt) | análogos de fosfonato anti-cáncer | |
| BRPI0415759A (pt) | compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia | |
| TN2010000136A1 (en) | Composition comprising sphingosine 1 phosphate (s1p) receptor modulators | |
| EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
| GT200500119A (es) | Derivados de tetraazabenzo [e] azuleno y sus analogos | |
| BRPI0817060A2 (pt) | composto, processo para a preparação destes compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são modulados por agonistas receptores de hormônio da tireóide e usos destes compostos | |
| BR122013028005B8 (pt) | compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos | |
| MY145613A (en) | Novel compounds | |
| AR035348A1 (es) | Indoles sustituidos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la preparacion de medicamentos | |
| BR0207871A (pt) | Composição para liberar bisfosfonato para um alvo | |
| BRPI0705106A (pt) | composições de toner | |
| BRPI0715746B8 (pt) | composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo | |
| PA8576101A1 (es) | Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| UY30558A1 (es) | Derivados de pirazol como agentes antiagregantes plaquetarios y antitromboticos | |
| BR0317222A (pt) | Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |